Zentalis :
Focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer. In addition to its lead program, ZN-c5, an oral SERD for estrogen receptor positive, HER2-negative breast cancer, the Company is developing a broad pipeline of oncology candidates, targeting areas of major unmet medical need. The Company has offices in New York and San Diego.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Disease Space
Oncology
Listing
Public, USA
Market Cap
1B +
Website:
Profiles:
Address:
530 Seventh Avenue, Ste 2201
Corner of 39 St
New York, NY 10018
United States
Corner of 39 St
New York, NY 10018
United States
Company Participants at Solebury Trout CEO & Investor Ski Conference 2020
- Anthony Sun, CEO
- Melissa Epperly, CFO
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Lead Programs
ZN-c5: Oral SERD
oral selective estrogen receptor degrader (SERD)
| Indication | Phase |
|---|---|
| Breast Cancer | 1/2 |
ZN-c3: WEE1
oral inhibitor of WEE1
| Indication | Phase |
|---|---|
| Solid Tumors | 1/2 |
ZN-d5: BCL-2
oral selective inhibitor of B-cell lymphoma 2 (BCL-2)
| Indication | Phase |
|---|---|
| Hematologic Malignancies | IND |
ZN-e4: EGFR
oral, small molecule inhibitor of mutant epidermal growth factor receptor (EGFR)
| Indication | Phase |
|---|---|
| NSCLC | 1/2 |
Top 10 Holders of Zentalis Pharmaceuticals, Inc.
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Viking Global Investors LP | 12.38 | 4,443,284 | 189.02 | Stakes | 2020-04-07 |
| Matrix Capital Management Co. LP | 10.65 | 3,821,739 | 162.58 | Stakes | 2020-04-03 |
| Tybourne Capital Management (HK) Ltd. | 7.43 | 2,664,409 | 113.34 | Stakes | 2020-05-29 |
| Citadel Advisors LLC | 5.94 | 2,129,964 | 90.61 | Stakes | 2020-04-03 |
| Fidelity Management & Research Co. LLC | 5.91 | 2,119,451 | 90.16 | Funds | 2020-05-31 |
| AllianceBernstein LP | 0.70 | 251,344 | 10.69 | Funds | 2020-05-31 |
| Polar Capital LLP | 0.70 | 250,000 | 10.64 | Funds | 2020-05-29 |
| Franklin Advisers, Inc. | 0.21 | 73,700 | 3.14 | Funds | 2020-05-31 |
| The Vanguard Group, Inc. | 0.08 | 28,894 | 1.23 | Funds | 2020-05-31 |
| Geode Capital Management LLC | 0.05 | 19,037 | 0.81 | Funds | 2020-05-31 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.